What is the prevalence of Pyruvate Kinase Deficiency?

Pyruvate Kinase Deficiency is a rare, inherited metabolic disorder with an estimated global prevalence ranging from 1 in 20,000 to 1 in 300,000 individuals, though these figures likely underestimate the true frequency due to diagnostic challenges. Because Pyruvate Kinase Deficiency often presents with variable clinical severity, many cases remain undiagnosed or misattributed to other hemolytic anemias.

What is the estimated prevalence and incidence of Pyruvate Kinase Deficiency?

While exact global numbers are difficult to ascertain, Pyruvate Kinase Deficiency is considered a rare disease. In populations of European descent, the prevalence of symptomatic Pyruvate Kinase Deficiency is often cited at approximately 1 in 20,000. However, data from the NIH GARD and Orphanet suggest that the actual incidence may vary significantly based on geographic region and carrier frequency, as the condition is autosomal recessive and requires two pathogenic mutations to manifest.

Does Pyruvate Kinase Deficiency affect specific populations or genders differently?

Pyruvate Kinase Deficiency affects males and females equally, as the causative gene (PKLR) is located on chromosome 1. There is no known ethnic predilection, though certain founder mutations have been identified in specific populations. At DiseaseMaps.org, 6 members have shared their experiences, providing a valuable, albeit small, real-world perspective on the diverse ways this condition manifests across different demographics.

What are the challenges in determining accurate prevalence?

Determining the precise number of people living with Pyruvate Kinase Deficiency is complicated by several factors:

• Variable Phenotype: Symptoms range from mild, compensated hemolysis to severe, transfusion-dependent anemia.


• Underdiagnosis: Patients with milder forms may not seek medical attention or may be misdiagnosed with other red blood cell disorders.


• Diagnostic Complexity: Specialized enzyme assays or genetic testing are required to confirm a diagnosis, which may not be accessible in all clinical settings.

At what age does Pyruvate Kinase Deficiency typically appear?

Pyruvate Kinase Deficiency is a lifelong condition. The age of onset is typically pediatric, often presenting in the neonatal period with severe jaundice or anemia, though some individuals may not be diagnosed until adulthood during routine blood work or during times of physiological stress.

Next steps

• Consult a hematologist specializing in red blood cell enzymopathies to discuss testing.


• Connect with the DiseaseMaps.org community to share experiences with others living with this rare condition.


• Review resources from the Pyruvate Kinase Deficiency Foundation for information on clinical trials and registries.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: Pyruvate kinase deficiency of erythrocytes (ORPHA:763).


• NIH Genetic and Rare Diseases (GARD) Information Center: Pyruvate kinase deficiency.


• Online Mendelian Inheritance in Man (OMIM): #266200.


• Pyruvate Kinase Deficiency Foundation: Patient resource and education hub.